PF-08046876

N/A

Report date: 2026/04/28 09:38:50

Base Information

Drug NamePF-08046876
Drug Alias NamePF-08046876
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > β-glucuronide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > AMDCPT payload
Mechanisms of ActionAnti-ITGB6DNA topoisomerase I inhibitors
TargetsIntegrin beta-6DNA topoisomerase I
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPuerto Rico +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaIND
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A